Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence
- PMID: 19640210
- DOI: 10.1517/14656560903140533
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence
Abstract
Poor therapeutic adherence is a major issue faced by physicians today. This paper summarizes the adherence rates with oral bisphosphonate (OBP) treatment in clinical practice and their impact on clinical outcomes. Studies systematically demonstrated that overall compliance and persistence with OBPs among osteoporotic women are poor. Although extending dosing intervals improved adherence, the gains are suboptimal. Most importantly, low compliance and persistence rates consistently resulted in increased rates of fractures. The results emphasize the importance of adherence to treatment to achieve optimal antifracture efficacy. There is an urgent need to implement strategies and to encourage physicians to take measures that increase patients' awareness of the need to use osteoporosis medications as directed in order to benefit from them fully.
Similar articles
-
Improving compliance and persistence with bisphosphonate therapy for osteoporosis.Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. doi: 10.1016/j.amjmed.2005.12.019. Am J Med. 2006. PMID: 16563937 Review.
-
Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.Curr Med Res Opin. 2007 Oct;23(10):2517-29. doi: 10.1185/030079907X226339. Curr Med Res Opin. 2007. PMID: 17825128 Clinical Trial.
-
Adherence and persistence: impact on outcomes and health care resources.Bone. 2006 Feb;38(2 Suppl 2):S18-21. doi: 10.1016/j.bone.2005.11.013. Epub 2006 Jan 27. Bone. 2006. PMID: 16443406 Review.
-
The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.Curr Med Res Opin. 2007 Dec;23(12):3137-52. doi: 10.1185/030079907X242890. Curr Med Res Opin. 2007. PMID: 17988435
-
Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.Am J Med. 2006 Apr;119(4 Suppl 1):S12-7. doi: 10.1016/j.amjmed.2005.12.018. Am J Med. 2006. PMID: 16563936 Review.
Cited by
-
Systematic evidence of health economic evaluation of drugs for postmenopausal osteoporosis: A quality appraisal.Osteoporos Sarcopenia. 2020 Jun;6(2):39-52. doi: 10.1016/j.afos.2020.05.006. Epub 2020 Jun 23. Osteoporos Sarcopenia. 2020. PMID: 32715093 Free PMC article. Review.
-
Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.Clin Drug Investig. 2012 Feb 1;32(2):121-9. doi: 10.2165/11597990-000000000-00000. Clin Drug Investig. 2012. PMID: 22185631
-
Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.BMC Musculoskelet Disord. 2014 Apr 1;15:112. doi: 10.1186/1471-2474-15-112. BMC Musculoskelet Disord. 2014. PMID: 24684864 Free PMC article.
-
Persistence with osteoporosis medication among newly-treated osteoporotic patients.J Bone Miner Metab. 2013 Sep;31(5):562-70. doi: 10.1007/s00774-013-0440-2. Epub 2013 Apr 11. J Bone Miner Metab. 2013. PMID: 23575910
-
Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations.Ther Adv Chronic Dis. 2010 Nov 1;1(4):149-162. doi: 10.1177/2040622310376137. Ther Adv Chronic Dis. 2010. PMID: 22282723 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical